Development

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

Articles

In a pandemic, genetic vaccines offer several advantages over traditional approaches.

Genetic Vaccine Platforms Demonstrate Their Potential

Jennifer Markarian is manufacturing editor of BioPharm International.

Homology Medicines discusses how the clinical-stage biopharmaceutical company met its need for supply of adeno-associated virus vectors.

Finding Success in AAV Manufacturing

Using rDNA technology to synthesize production of proteins and peptide hormones, the biotech startup has achieved synthetic production of insulin, potentially lowering insulin cost by 30%. 

rBIO Hits Key Lab Milestone with Synthetic Production of Insulin

CDMO Avid Bioservices will provide development and drug substance manufacturing for Oragenics’ novel COVID-19 vaccine candidate, Terra CoV-2. 

Oragenics and Avid Bioservices Collaborate on Coronavirus Vaccine

CordenPharma announces expansion of lipid excipients supply for coronavirus vaccine scale up.

CordenPharma Expands Lipid Supply for Moderna

Therapies for early and late treatment and passive immunization of COVID-19 are needed and can be developed using antibodies from recovered patients.

Plasma-Based Antibody Therapies Battle Against COVID-19

Biopharma companies responding to the COVID-19 outbreak think accelerating the development of vaccines is safe.

Can Vaccine Development Be Safely Accelerated?

An evaluation by USP indicates bovine heparin is a potential alternative to porcine heparin.

Bovine Heparin Meets Acceptable Impurity Levels

The new GMP conditioning product offering is designed to support clinical phase and commercialization stages of cell and gene therapy production.

Polyplus-transfection Expands GMP Portfolio for Gene and Cell Therapy Manufacturing

Innovation in manufacturing technologies must occur to ensure the availability of gene and cell therapies.

API Synthesis and Manufacturing, Large Molecule